Skin cancer kills roughly 60,000 people worldwide each year from melanoma alone, with thousands more dying from other skin cancer types. In the United States, an estimated 8,510 people will die of melanoma in 2026, accounting for about 1.4% of all cancer deaths. Those numbers represent a disease that is highly survivable when caught early but dangerous when it spreads.
Global Deaths From Skin Cancer
Melanoma is the deadliest form of skin cancer, responsible for about 58,667 deaths globally in 2022 according to the International Agency for Research on Cancer. That same year, roughly 330,000 new melanoma cases were diagnosed worldwide. So while melanoma makes up a relatively small share of all skin cancers, it causes the vast majority of skin cancer deaths.
The other major types, basal cell carcinoma and squamous cell carcinoma, are far more common but far less lethal. In the United States, estimates for annual deaths from these non-melanoma skin cancers range from about 2,000 to 8,000, with squamous cell carcinoma responsible for most of those. Because many countries don’t track non-melanoma skin cancers in their registries, a precise global death toll for all skin cancer types combined is difficult to pin down, but it likely exceeds 70,000 per year.
Deaths in the United States
The National Cancer Institute projects 112,000 new melanoma cases and 8,510 melanoma deaths in the U.S. in 2026. Melanoma accounts for about 1.4% of all cancer deaths in the country. Adding in deaths from squamous and basal cell carcinomas, the total U.S. skin cancer death toll likely falls somewhere between 10,000 and 16,000 per year.
To put that in perspective, melanoma kills fewer Americans than lung, colon, or breast cancer, but more than several other well-known cancers. The gap between the high number of diagnoses and the relatively lower death count reflects the fact that most cases are caught before they become life-threatening.
Why Stage at Diagnosis Matters So Much
Skin cancer survival depends heavily on how far the disease has progressed when it’s found. The five-year relative survival rates for melanoma tell a striking story:
- Localized (Stages I-II): 97.6% five-year survival. The cancer is still confined to the skin.
- Regional (Stage III): 60.3% five-year survival. The cancer has reached nearby lymph nodes or tissues.
- Distant (Stage IV): 16.2% five-year survival. The cancer has spread to distant organs.
That gap, from nearly 98% survival down to about 16%, explains why early detection is the single biggest factor separating people who survive melanoma from those who don’t. A melanoma caught while it’s still thin and localized to the skin is almost always curable. Once it metastasizes to the liver, lungs, or brain, treatment options become far more limited and outcomes drop sharply.
Who Is Most at Risk of Dying
Skin cancer doesn’t affect everyone equally. Men are diagnosed with melanoma at higher rates than women and are more likely to die from it. Part of this gap is behavioral: men are less likely to use sunscreen, less likely to perform skin self-checks, and statistically present with thicker, more advanced tumors at the time of diagnosis.
Age plays a major role as well. While melanoma can occur in younger adults (it’s one of the more common cancers in people under 30), deaths are concentrated among older populations. The median age at melanoma diagnosis is around 66, and death rates climb steeply after age 50. Older adults are more likely to have melanomas that have been growing unnoticed for years, and their tumors tend to be biologically more aggressive.
People with fair skin, a history of sunburns, many moles, or a family history of melanoma face the highest risk of developing the disease. However, skin cancer can occur in people of all skin tones, and melanomas in people with darker skin are often diagnosed at later stages, leading to worse outcomes despite lower overall incidence.
Why Most Skin Cancers Don’t Kill
Basal cell carcinoma, the most common cancer of any kind in humans, is responsible for millions of diagnoses each year but very rarely causes death. It grows slowly, almost never spreads beyond the original site, and is typically removed with a simple outpatient procedure. Squamous cell carcinoma is slightly more aggressive and can occasionally metastasize, which is why it accounts for most non-melanoma skin cancer deaths, but even it has a high cure rate when treated early.
Melanoma is different. It arises from the pigment-producing cells in the skin and has a much greater tendency to invade deeper tissue and spread through the bloodstream or lymphatic system. A melanoma only a few millimeters thick can seed distant metastases, which is why even small suspicious moles warrant prompt evaluation. Newer immunotherapy treatments have improved survival for advanced melanoma significantly over the past decade, but the disease remains dangerous once it reaches Stage IV.
The Numbers in Context
Roughly 60,000 people die of melanoma each year worldwide, with additional thousands dying from squamous and basal cell cancers. In the U.S., the combined toll is likely 10,000 to 16,000 deaths per year. These numbers make skin cancer one of the more survivable cancer types overall, but the sheer volume of cases means the absolute death toll remains substantial. The nearly 98% survival rate for early-stage melanoma underscores a consistent pattern: the people who die from skin cancer are overwhelmingly those whose disease was found too late.